Drug
rFVIIa
rFVIIa is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
1(20%)
Results Posted
25%(1 trials)
Phase Distribution
Ph phase_3
2
40%
Ph phase_2
2
40%
Ph phase_4
1
20%
Phase Distribution
0
Early Stage
2
Mid Stage
3
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
1(20.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(4)
Detailed Status
Completed4
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 22 (40.0%)
Phase 32 (40.0%)
Phase 41 (20.0%)
Trials by Status
completed480%
recruiting120%
Recent Activity
1 active trials
Showing 5 of 5
recruitingphase_3
SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
NCT04563520
completedphase_3
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors
NCT02622321
completedphase_2
"Spot Sign" Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy
NCT01359202
completedphase_4
rhuFVIIa in Post-partum Hemorrhage
NCT00370877
completedphase_2
Efficacy and Safety of Factor VIIa on Rebleeding After Surgery for Spontaneous Intracerebral Hemorrhage (ICH)
NCT00128050
Clinical Trials (5)
Showing 5 of 5 trials
NCT04563520Phase 3
SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
NCT02622321Phase 3
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors
NCT01359202Phase 2
"Spot Sign" Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy
NCT00370877Phase 4
rhuFVIIa in Post-partum Hemorrhage
NCT00128050Phase 2
Efficacy and Safety of Factor VIIa on Rebleeding After Surgery for Spontaneous Intracerebral Hemorrhage (ICH)
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5